Phase Ib/II Clinical Trial of Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10 Humanized Monoclonal Antibody Injection in Adult Asthmatic Subjects
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Comekibart (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Shanghai Mabgeek Biotech
Most Recent Events
- 17 Aug 2023 Planned End Date changed from 20 Jul 2023 to 20 Jun 2024.
- 17 Aug 2023 Planned primary completion date changed from 20 Feb 2023 to 20 Dec 2023.
- 13 Jul 2022 Status changed from not yet recruiting to recruiting.